Edition:
United Kingdom

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

71.44USD
6:57pm BST
Change (% chg)

$-0.08 (-0.11%)
Prev Close
$71.52
Open
$71.69
Day's High
$71.76
Day's Low
$70.83
Volume
2,672,995
Avg. Vol
7,265,565
52-wk High
$89.54
52-wk Low
$64.27

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $107,268.80
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.52
Yield (%): 2.53

Financials

  GILD.O Industry Sector
P/E (TTM): 8.92 82.81 32.74
EPS (TTM): 9.21 -- --
ROI: 27.00 2.00 14.38
ROE: 63.92 3.49 16.08

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

20 Jun 2018

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

20 Jun 2018

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON, June 20 GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

20 Jun 2018

GSK's two-drug HIV treatment meets main goal in late stage studies

GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

14 Jun 2018

GSK's two-drug HIV treatment meets main goal in late stage studies

GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

14 Jun 2018

UPDATE 2-GSK's two-drug HIV treatment meets main goal in late stage studies

June 14 GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

14 Jun 2018

BRIEF-FDA Approves Expanded Indication For Truvada

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES EXPANDED INDICATION FOR TRUVADA® (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE) FOR REDUCING THE RISK OF ACQUIRING HIV-1 IN ADOLESCENTS

15 May 2018

BRIEF-Gilead Sciences Board Has Declared A Cash Dividend Of $0.57 Per Share Of Common Stock For Q2 Of 2018

* GILEAD SCIENCES INC - BOARD OF DIRECTORS HAS DECLARED A CASH DIVIDEND OF $0.57 PER SHARE OF COMMON STOCK FOR Q2 OF 2018 Source text for Eikon: Further company coverage:

01 May 2018

BRIEF-Gilead Sciences Reports Q1 EPS $1.17

* GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

01 May 2018

Gilead hepatitis C drug sales slump, shares fall 5 percent

Gilead Sciences Inc reported a lower quarterly profit on Tuesday as sales of its flagship hepatitis C drugs fell by a greater-than-expected 59 percent, sending shares of the biotechnology company down 5 percent.

01 May 2018

Earnings vs. Estimates